CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
-0.0001 (-33.33%)
Apr 29, 2026, 11:20 AM EST
CNBX Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
245.15K
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sorrento Therapeutics | 64.27M |
| EV Biologics | 9.47M |
| Regenerative Medical Technology Group | 5.04M |
| Emmaus Life Sciences | 12.45M |
| SQZ Biotechnologies Company | 12.12M |
| THC Farmaceuticals | 18.52K |
CNBX Pharmaceuticals News
- 3 years ago - CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - PRNewsWire
- 3 years ago - CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - PRNewsWire
- 3 years ago - CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - PRNewsWire
- 3 years ago - CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - PRNewsWire
- 3 years ago - CNBX Pharmaceuticals Announces New Patent Granted in Australia - PRNewsWire
- 4 years ago - CNBX Pharmaceuticals Granted Patent in Hong Kong - PRNewsWire
- 4 years ago - Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals - PRNewsWire
- 4 years ago - CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials - PRNewsWire